| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/21/2010 | WO2010008084A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | WO2010008069A1 Cell proliferation inhibitor |
| 01/21/2010 | WO2010008023A1 Bone elongation promoter |
| 01/21/2010 | WO2010008001A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | WO2010007701A1 Therapeutic agent and test agent for disease with myocardial necrosis |
| 01/21/2010 | WO2009146033A3 Compositions and methods for modulating smn activity |
| 01/21/2010 | WO2009137689A3 Delivery of nucleic acid complexes from particles |
| 01/21/2010 | WO2009128936A3 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants |
| 01/21/2010 | WO2009117116A3 Heat shock protein gp96 vaccination and methods of using same |
| 01/21/2010 | WO2009108217A3 Compositions comprising k-ras sirna and methods of use |
| 01/21/2010 | WO2009018492A3 Micro-rnas that control myosin expression and myofiber identity |
| 01/21/2010 | US20100016654 Methods of Minimizing Immunological Rejection of A Nuclear Transfer Fetus |
| 01/21/2010 | US20100016549 Peyer's patch and/or m-cell targeting ligands |
| 01/21/2010 | US20100016415 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines |
| 01/21/2010 | US20100016414 Targets for human micro rnas in avian influenza virus (h5n1) genome |
| 01/21/2010 | US20100016404 Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| 01/21/2010 | US20100016228 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 01/21/2010 | US20100015712 Side population cells originated from human amnion and their uses |
| 01/21/2010 | US20100015700 Use of the adenoviral e2 late promoter |
| 01/21/2010 | US20100015200 Drug Delivery Medical Device |
| 01/21/2010 | US20100015176 Settings for recombinant adenoviral-based vaccines |
| 01/21/2010 | US20100015167 in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells; vaccine comprising a protein that comprises human sucrase isomaltase protein |
| 01/21/2010 | US20100015150 Tdf-related compounds and analogs thereof |
| 01/21/2010 | US20100015132 Uses of mammalian cytokines and agonists; related reagents |
| 01/21/2010 | US20100015108 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 01/21/2010 | US20100015087 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 01/21/2010 | CA2736311A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | CA2730923A1 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use |
| 01/21/2010 | CA2730796A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | CA2730498A1 Medical devices and methods for delivery of nucleic acids |
| 01/21/2010 | CA2690838A1 Anti-cancer composition comprising microrna molecules |
| 01/20/2010 | EP2145961A2 Porcine adenovirus type 3 genome |
| 01/20/2010 | EP2145958A1 Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease |
| 01/20/2010 | EP2145897A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/20/2010 | EP2145628A1 Treatment of neurodegenerative disease through intracranial delivery of short interfering RNA (siRNA) |
| 01/20/2010 | EP2145189A2 Papillomavirus pseudoviruses for detection and therapy of tumors |
| 01/20/2010 | EP2145002A2 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| 01/20/2010 | EP2003140B1 Galactose derivative, drug carrier and medicinal composition |
| 01/20/2010 | EP1977246B1 Na+, k+-atpase expression in cervical dysplasia and cancer |
| 01/20/2010 | EP1443970B1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/20/2010 | EP1363995B1 Use of a composition comprising n-acetylcysteine for conditioning stem cells |
| 01/20/2010 | EP0971724B1 Expression of active human factor ix in mammary tissue of transgenic animals |
| 01/20/2010 | EP0917538B1 Eukaryotic cells expressing at their surface at least an hla-g isoform and their applications |
| 01/20/2010 | CN101628118A Influenza compound multi-epitope DNA vaccine and application thereof |
| 01/20/2010 | CN101628111A TACI-immunoglobulin fusion proteins |
| 01/20/2010 | CN100582230C Expression of endogenous genes by non-homologons recombination of a vector construct with cellular DNA |
| 01/20/2010 | CN100582117C Compositions for DNA mediated gene silencing |
| 01/19/2010 | US7649088 Diagnosis and treatment of Hereditary Spastic Paraplegia |
| 01/19/2010 | US7649082 Glial-derived neurotrophic factor (GDNF)/neurturin family of growth factors; Neurodegenerative disorders; used in preventing the atrophy, degeneration or death of certain cells, in particular neurons |
| 01/19/2010 | US7648827 Use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferative diseases |
| 01/19/2010 | US7648826 Detecting CYP24 expression level as a marker for predisposition to cancer |
| 01/14/2010 | WO2010006111A2 Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer |
| 01/14/2010 | WO2010005704A2 Novel helper plasmid, defective sindbis viral vectors and methods of use thereof |
| 01/14/2010 | WO2010005474A1 Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens |
| 01/14/2010 | WO2010005365A1 Unprocessed rolling circle amplification product |
| 01/14/2010 | WO2010005296A1 Polypeptides involved in the neuroregeneration-promoting properties of olfactory ensheathing glia |
| 01/14/2010 | WO2010005069A1 Immunity-inducing agent and method for detection of cancer |
| 01/14/2010 | WO2010005055A1 Oligonucleotide structure, and method for regulation of gene expression |
| 01/14/2010 | WO2010005046A1 Anti-angiogenic agent |
| 01/14/2010 | WO2010004816A1 Inhibitor of degranulation of mast cell |
| 01/14/2010 | WO2010004283A2 Therapy |
| 01/14/2010 | WO2009142822A9 2-f modified rna interference agents |
| 01/14/2010 | WO2009126306A8 Compositions and methods for detecting egfr mutations in cancer |
| 01/14/2010 | WO2009120371A3 Computationally designed inhibitors of amyloidosis |
| 01/14/2010 | WO2009105759A9 Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof |
| 01/14/2010 | WO2006110413A9 Haemophilus influenzae type b |
| 01/14/2010 | WO2005041874A9 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells |
| 01/14/2010 | WO2003012125A9 Mre11: modulation of cellular proliferation |
| 01/14/2010 | US20100010207 Rna interference mediating small rna molecules |
| 01/14/2010 | US20100010201 Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
| 01/14/2010 | US20100010200 for Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction |
| 01/14/2010 | US20100010196 Compositions and methods for non-targeted activation of endogenous genes |
| 01/14/2010 | US20100010074 Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control |
| 01/14/2010 | US20100010073 Microrna (mirna) for the diagnosis and treatment of heart diseases |
| 01/14/2010 | US20100010070 Use of nucleic acid sequences for the treatment of neuralogical and psychiatric diseases and compositions |
| 01/14/2010 | US20100010068 Liver-directed gene therapy |
| 01/14/2010 | US20100010067 Arginine-conjugated bioreducible poly(disulfide amine) polymers for gene delivery system |
| 01/14/2010 | US20100010064 Cancer treatment by combined inhibition of proteasome and telomerase activities |
| 01/14/2010 | US20100009914 Method of protecting sensitive molecules from a photo-polymerizing environment |
| 01/14/2010 | US20100009909 Peptides binding the phosphatase 2a protein |
| 01/14/2010 | US20100009366 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications |
| 01/14/2010 | US20100009363 RBP4 In Insulin sensitivity/resistance, diabetes, and obesity |
| 01/14/2010 | US20100008964 Isolated stromal cells and methods of using the same |
| 01/14/2010 | US20100008947 Porcine adenovirus e1 and e4 regions |
| 01/14/2010 | US20100008946 Microorganisms for therapy |
| 01/14/2010 | US20100008941 vaccination directed against the hepatitis C virus (HCV); |
| 01/14/2010 | US20100008903 Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment |
| 01/14/2010 | US20100008901 Methods for the treatment and prevention of cancer |
| 01/14/2010 | US20100008892 Quality assays for antigen presenting cells |
| 01/14/2010 | CA2730088A1 Immunity-inducing agent and method for detection of cancer |
| 01/14/2010 | CA2726945A1 Polypeptides involved in the neuroregeneration-promoting properties of olfactory ensheathing glia |
| 01/13/2010 | EP2143794A1 Viral vector for gene therapy |
| 01/13/2010 | EP2142217A2 Method for detecting autoprocessed, secreted pcsk9 |
| 01/13/2010 | EP1701737B1 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 01/13/2010 | EP1558749B1 Atypical protein kinase c isoforms in disorders of the nervous system and cancer |
| 01/13/2010 | EP1499886B1 Methods and compositions for inducing an immune response |
| 01/13/2010 | EP1323415B1 Method of coating fine particle with lipid film |
| 01/13/2010 | CN100580085C Adenovirus/alpha virus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells |
| 01/13/2010 | CN100580080C Corona-virus-like particles comprising functionally deleted genomes |
| 01/13/2010 | CN100579579C Anti-cancer and anti-infectious disease compositions and methods for using same |